A new study released by Biotechnology Industry Organization (BIO) Industry Analysis and Ipreo shows that investors are optimistic on biotechís future and investment in biotechnology will continue to perform well. Findings from the study will be presented at the Closing Plenary session of the 13th annual BIO CEO & Investor Conference, taking place February 14-15 in New York City at the Waldorf-Astoria. Full details on the study will be posted to the BIO Industry Analysis site immediately following the Plenary session on Tuesday, February 15.
Key findings from the study include:
- More than 86 percent of investors surveyed believe that the major biotech indices will end up in positive territory for 2011, with 35 percent forecasting double digit returns.
- Nearly 55 percent of investors believe that biotech will outperform the rest of the healthcare sector in 2011.
- Investors surveyed are more likely to invest in companies with late stage clinical development versus early stage.
- More than 88 percent believe that there are going to be the same or more IPOs in 2011 compared to 2010.